OncoLink

September, 2004 Sponsored by Aventis Oncology
In this Issue

Scientific Findings: Read OncoLink's special reports from the annual American Society of Clinical Oncology with in-depth, up-to-the-minute coverage of sessions and presentations discussing prostate cancer.

Association between androgen deprivation therapy and fracture risk:  A population-based cohort study in men with non-metastatic prostate cancer.  

Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911)

The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer

A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer

SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA)

Ask The Experts about Prostate Cancer
This is your chance to "Ask the OncoLink Experts" everything you've always wanted to know about cancer.

OncoLink PollOncoLink Monthly Poll: Did you get more than one opinion on your cancer care?

OncoLink SurveyComplementary And Alternative Therapies Survey We are collecting information to better understand the use of therapies that are not typically prescribed by doctors or given in hospitals for cancer care.

 

September is ...

Prostate Cancer Awareness Month
Join OncoLink in helping to educate all men about the importance of early detection, treatment and research advances made to eliminate this disease. Visit our Prostate Cancer Menu for more information.


Harry Belafonte Speaks Up Against Prostate Cancer

Harry Belafonte speaks to OncoLink
Mr. Belafonte speaks about his diagnosis and treatment, and how he triumphed over this disease.

Contact Us   |   Unsubscribe   |   Privacy Policy